NCT00273039

A Study Of A New Medicine (GW679769) For The Treatment Of Social Anxiety Disorder

A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Forced Dose Titration Study Evaluating the Efficacy and Safety of GW679769 and Paroxetine in Subjects With Social Anxiety Disorder

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 242 (actual)
• Sponsor: GlaxoSmithKline · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to test the safety and efficacy of GW679769 and paroxetine in subjects with Social Anxiety Disorder

Conditions

• Social Anxiety Disorder
• Anxiety Disorders

Interventions

Type	Name	Description
DRUG	paroxetine

Timeline

• Start date: 2005-08-01
• Primary completion: 2006-09-01
• Completion: 2006-09-01
• First posted: 2006-01-09
• Last updated: 2016-10-26

Locations

27 sites across 6 countries: United States, Argentina, Canada, Chile, Costa Rica, Mexico